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Summary
The emphasis on eliminating racial and ethnic disparities in health care has received national
attention, with various policy initiatives addressing this problem and proposing solutions.
However, in the current economic era requiring tight monetary constraints, emphasis is
increasingly being placed on economic efficiency, which often conflicts with the equality doctrine
upon which many policies have been framed. Our review aims to highlight the disparity
implications of one such policy provision—the predominantly utilization-based eligibility criteria
for medication therapy management (MTM) services under Medicare Part D—by identifying
studies that have documented racial and ethnic disparities in health status and the use of and
spending on prescription medications. Future design and evaluation of various regulations and
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legislations employing utilization-based eligibility criteria must use caution in order to strike an
equity-efficiency balance.
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Introduction
The Report of the Secretary’s Task Force on Black and Minority Health, released by the
Department of Health and Human Services (HHS) in 1985, was the first comprehensive
report released by the U.S. government that addressed racial and ethnic disparities in health
care [1, 101]. This report highlighted the “national paradox” characterized by the
simultaneous existence of phenomenal scientific progress leading to overall improvements
in population health status coupled with prevalent and significant health care disparities
among the minority groups in America [101]. Ever since then, a steady flow of studies and
reports have attempted to document racial and ethnic disparities in the myriad facets of
health and health care in the United States.

NIH-PA Author Manuscript

Many reports documenting significant racial and ethnic inequities in access to care and in
use of health care services for different diseases and health conditions have changed the
landscape considerably [2, 3, 4]. There is now a heightened sense of awareness and
cognizance of racial and ethnic disparities in health care, which in turn, has led to the
formulation and implementation of many newer policies and programs intended to tackle
this issue. The Department of Health and Human Services (HHS) unveiled the HHS Action
Plan to Reduce Racial and Ethnic Health Disparities, in 2011 [102]. This initiative provides
a framework to the federal agency to collaborate with other public and private agencies as
well as communities to work toward creating a health care system free of disparities [1].
Healthy People 2020 has made elimination of disparities one of its four overarching goals to
be achieved by 2020 [5, 103]. Thus, more resources and research need to be devoted to not
only identifying the root causes of racial and ethnic disparities but also to assessing the
impact of various policies and legislations to ensure equitable access to and utilization of
health care resources among all sections of the population.
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A well-established and widely cited theoretical framework to understand disparities was
developed by Dr. Camara Phyllis Jones of the Centers for Disease Control and Prevention
[6]. The framework depicts three levels of causes of racial disparities: institutionalized,
personally mediated, and internalized. Institutionalized disparities refer to a system in which
differential access to goods, services, and opportunities of society by race is normalized,
legalized, and structured to the extent that it has been “codified in our institutions of custom,
practice, and law, so there need not be an identifiable perpetrator” [6, p. 1212]. Personally
mediated disparities arise from both prejudice and discrimination because of “differential
assumptions about the abilities, motives, and intentions of others, and differential actions
toward others, according to their race” [6, p. 1212–1213]. Finally, internalized disparities
occur when there is “acceptance by members of the stigmatized races of negative messages
about their own abilities and intrinsic worth” and as a result, they do not believe in
themselves and in those who share their appearance [6, p. 1213]. Among the three causes,
the institutionalized cause of racial and ethnic disparities is more relevant to the discussions
of disparities related to health policy.
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The Medicare Modernization Act of 2003 (MMA) included a requirement that prescription
drug plans must provide medication therapy management (MTM) services to certain
Medicare Part D beneficiaries [7]. MTM services consist of a distinct list of services
intended to optimize therapeutic outcomes [8]. At the core of these services lies the
formulation of a medication treatment plan by pharmacists or other health care providers and
the integration of medication management within the broader context of all health services
provided to patients for the purpose of optimizing therapeutic outcomes [9]. According to
the Centers for Medicare and Medicaid Services (CMS) and MMA guidelines, Part D plans
are required to provide the MTM services to beneficiaries who meet the following three
criteria: (1) individuals with a minimum of three chronic conditions, (2) individuals taking a
minimum of eight prescriptions, and/or (3) individuals with an annual drug cost of $3,000 or
more [104]. The value of MTM for chronic disease management, including diabetes and
hypertension, has been widely recognized in the scientific literature, by government
agencies, and by the 2010 Patient Protection and Affordable Care Act (PPACA) [10–13,
105]. These services are extremely important for Medicare beneficiaries because more than
80% of the elderly have one or more chronic conditions, and 65% have at least two chronic
conditions [14]. In addition, several chronic conditions, including diabetes and hypertension,
contributed significantly to the increase in Medicare spending from 1997 to 2006 [15].
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Policy makers in pursuit of achieving economic efficiency may neglect the impact of new
policies or regulations on equity. With the current economic downturn, tight fiscal budgetary
constraints may be imposed on various legislations and policy initiatives. Implementations
of value-based strategies therefore become more likely when public and private payers in the
U.S. are designing future insurance policies to improve economic efficiency. MTM, with its
utilization-based eligibility requirements, can be viewed as a value-based strategy because
individuals with complex drug regimens (i.e., using a greater number of medications) and
higher spending on medications are deemed more likely to benefit from the MTM services.
However, as observed by Wang and colleagues in their analysis of MTM eligibility criteria
using the Medical Expenditure Panel Survey (MEPS) data, Hispanic and African American
beneficiaries had a lower likelihood of meeting MTM eligibility criteria when compared to
Whites [16]. This pattern of racial/ethnic disparity was observed both based on the original
MTM eligibility criteria in 2006 (range of odds ratios [ORs] for Blacks = 0.36–0.60, P<0.05;
range of ORs for Hispanics = 0.13–0.46, P<0.05), and the new criteria (described above)
that began in 2010 (range of ORs for Blacks = 0.65–0.71, P<0.05; range of ORs for
Hispanics = 0.48–0.59, P<0.05) [16]. In addition, among the Medicare beneficiaries with
severe health problems, similar patterns of disparities between the two minority groups and
Whites were observed. These findings suggest that utilization-based eligibility criteria, such
as those for MTM services under Medicare Part D, may have unintended consequences
leading to the preclusion of certain vulnerable populations from accessing these services.
These unintended consequences may have an inherent racial and ethnic bias or widen the
racial and ethnic disparities [16].
For decades, researchers have documented the extent to which disparities exist and the
sources that contribute to these disparities. The evidence thus generated has proved pivotal
in shifting focus towards implementing policies to tackle disparities and inequalities in
health and health care in countries such as the United States and the United Kingdom [17].
The empirical evidence documenting racial and ethnic disparities in the use and costs of
prescription drugs is abundant, with most of the reports indicating persistent disparities
between minorities and their majority counterparts. Our objective was to document the
differences in the use of, and expenditures on prescription medications and the differences in
health status across various racial and ethnic groups to highlight the disparity implications of
utilization-based eligibility criteria, such as those of MTM under Part D. CMS is cognizant
of the fact that these MTM eligibility criteria may lead to disparities, and has acknowledged
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.
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that it is willing to further alter the eligibility criteria in future rulemaking, provided that the
findings of Wang and colleagues are validated by it [104]. Our literature review would help
the academic community and the policy makers to better understand how utilization-based
MTM eligibility criteria would lead to racial and ethnic disparities in meeting these criteria.
Our purpose is to represent the general patterns exhibited in the literature, rather than present
an exhaustive review of the literature. We have divided the empirical studies from our
review into three sections: studies documenting disparities in the Medicare population, those
in the Medicaid population, and finally those in the general population. Evidence suggests
that health insurance plans other than Part D plans have not only included MTM programs,
but some have even followed the Part D MTM eligibility criteria [18, 106]. It is evident that
Medicare plays the role of a catalyst in the design of MTM plans offered to the nonMedicare population. Considering this, we have included the Medicaid and the general
population to highlight the fact that disparities arising from the utilization-based eligibility
criteria would not only affect the Medicare population, but the non-Medicare population as
well.

Methods

NIH-PA Author Manuscript

We used the PubMed database to search for studies that were conducted in the United States
and published in peer-reviewed journals between 1985 and 2011. This time period was
chosen because 1985 was the year when the HHS released its Report of the Secretary’s Task
Force on Black and Minority Health. “Race”, “ethnic”, “disparities”, “prescription
medications”, “access”, “utilization”, “expenditures”, “health status”, “Medicare”,
“Medicaid”, were the search terms used in various combinations. These search methods led
to the finding of 348 publications. From these search results, we selected only those studies
which 1) addressed racial and ethnic disparities in health status or prescription drug use and
expenditures in the Medicare, Medicaid, or general population, and 2) presented robust
quantitative data with original findings. The reference lists of selected articles were also
examined to include additional relevant studies. Rather than providing exhaustive
information from the 110 studies which were selected using these criteria, we narrowed the
focus of this review by including newer studies among studies on similar disease states and
drug categories. Although our review was not meant to be comprehensive, or to study
publication bias, a pattern did become obvious that most studies found reported significant
racial and ethnic disparities.

Results
Medicare population

NIH-PA Author Manuscript

Studies that have focused on the influence of race and ethnicity on medication use and
prescription drug spending among the Medicare population have generally reported
disparities between Blacks, Hispanics, and their White counterparts (Table 1). Using the
1999 Medicare Current Beneficiary Survey (MCBS) Cost and Use files, Briesacher and
colleagues compared drug coverage and prescription use by race and ethnicity for Medicare
beneficiaries with diabetes, hypertension, or heart disease [19]. The authors found that
Blacks and Hispanics used approximately 10 to 40% fewer medications on average and
spent up to 60% less in total drug costs than did Whites. Barring beneficiaries with Medicare
+ Choice coverage, significant disparities in medication use and expenditures were observed
between minorities and Whites with similar disease profiles and insurance status. The
authors speculated that the disparities observed in this study could be attributed to
socioeconomic differences among beneficiaries [19]. Using the 1999 MCBS Cost and Use
files, Gaskin and colleagues explored prescription drug spending and use among a sample of
Medicare beneficiaries [20]. They found that Black and Hispanic Medicare beneficiaries had
lower total spending (P<0.05) and out-of-pocket (OOP) spending (P<0.05) for prescription
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.
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drugs than did White beneficiaries. The authors concluded that the differences in OOP
spending could result from minorities having lower socioeconomic status and higher
likelihood of having Medicaid [20].
The 2003 MMA stipulated that beginning in 2006, prescription drug coverage for all
Medicare and Medicaid dual eligible enrollees would be shifted from Medicaid to Medicare
Part D [7]. Racial and ethnic disparities have also been documented in the prescription drug
utilization among these dually eligible beneficiaries. Philips and Atherly used the Medicaid
pharmacy claims data for dually eligible Medicare beneficiaries in a Medicaid home- and
community-based services (HCBS) program from four regions in Georgia [21]. They sought
to determine the prescription drug costs and their predictors for the study population.
African Americans were found to incur significantly lower drug expenditures in comparison
to Caucasians (P<0.01) in this study population [21]. Using claims data from 1995, Schore
and colleagues examined racial disparities in Medicaid pharmacy use among Black and
White dually eligible Medicare beneficiaries from the CMS’ dually eligible beneficiary
databases for 10 U.S. States [22]. They found that Blacks spent approximately 20% less per
month on prescription drugs than did White beneficiaries ($83 vs. $102) in all but one state
and used fewer drugs than did Whites in all of the states considered in that study [22].

NIH-PA Author Manuscript

Many reports have also documented drug-specific and disease-specific disparities including
those among beneficiaries diagnosed with cardiovascular diseases, mental disorders and
hypertension. Using the 1998 Health Plan Employer Data and Information Set (HEDIS),
Schneider and colleagues examined four measures of quality of care, one of which included
beta-blocker use after myocardial infarction [23]. They found that Black Medicare managed
care enrollees who had suffered heart attacks were less likely than were Whites to receive
beta-blockers (P<0.005). Using the MCBS data from 2001 to 2003, Zuckerman and
colleagues sampled Medicare beneficiaries with dementia [24]. Approximately 30% higher
use of anti-dementia medications was found among non-Hispanic Whites compared to other
racial and ethnic groups (P<0.05) [24]. Using two national databases of the Veterans Health
Administration, Poon and colleagues examined racial and ethnic differences in the use of,
and adherence to, medications in a cohort of veterans diagnosed with hypertension and
dementia [25]. In comparison to Whites, African Americans were found to have a lower
likelihood of receiving certain medications for hypertension such as angiotensin-converting
enzyme (ACE) inhibitors and angiotensin receptor blockers and dementia medications such
as acetylcholine esterase inhibitors and N-methyl-D-aspartate antagonists (P<0.05). Barring
ACE inhibitors, Hispanics were less likely to receive many other medications for
hypertension as compared to Whites (P<0.05) [25].

NIH-PA Author Manuscript

Empirical studies have also found racial and ethnic disparities in the prevalence and
management of certain chronic conditions such as diabetes, chronic kidney disease and HIV.
From their findings, Gornick and colleagues observed that nonelective surgeries, such as
lower limb amputations (6.03 vs. 1.74, per 1,000), and implantation of shunts or cannulae
for chronic renal dialysis (2.13 vs. 0.47, per 1,000), were performed more frequently among
Black Medicare beneficiaries as compared to Whites beneficiaries. These findings indicated
that Blacks were at a greater risk of undergoing surgical procedures associated with poor
management of chronic conditions such as diabetes and end stage renal disease (ESRD) [26,
27]. Using data from the Veterans Aging Cohort 3-Site Study (VACS 3), McGinnis and
colleagues examined disparities in survival among HIV-positive US veterans [28]. Black
and Hispanic veterans were found to have higher mortality rates (hazards ratio [HR]: 1.41;
95% CI: 1.19–1.66; and 1.41; 95% CI: 1.06–1.86, respectively) compared to Whites. In
addition, the proportion of veterans with four or more medical comorbidities (P<0.001) and
three or more HIV conditions (P=0.002) was higher among Blacks and Hispanics in
comparison to Whites [28].

Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.
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Using data from the Cooperative Cardiovascular Project Data for the years 1994 to 2004 of
Medicare patients diagnosed with myocardial infarction, Newsome and colleagues examined
racial differences in progression to ESRD [29]. African Americans were found to be at a
significantly greater risk of developing ESRD compared to Whites (HR: 1.90; 95% CI:
1.78–2.03), with the likelihood of incident ESRD being higher in African Americans at
various baseline estimate glomerular filtration rate (eGFR) levels (P<0.001) [29]. Using
MCBS data from 1992 to 2004, Ciol and colleagues examined racial and ethnic disparities in
disability-related outcomes such as limited mobility, activities of daily living (ADL), and
instrumental activities of daily living (IADL) [30]. Despite a slight overall decrease in the
ADL and IADL disability during this period, racial and ethnic disparities in disability
outcomes persisted, especially Black-White disparities (P<0.001). The authors attributed
these findings to factors such as access to health care and cultural differences in selfreporting of disability levels [30]. To examine the association of certain medical conditions
with racial disparities in disability rates, Whitson and colleagues analyzed data from a
cohort of adults >68 years participating in the Duke Established Populations for
Epidemiologic Studies of the Elderly [31]. They found that higher rates of obesity and
diabetes mellitus in Blacks contributed to more than 30% excess disability in them. Blacks
had a greater likelihood of being obese compared to Whites after adjusting for confounders
(OR: 1.73; 95% CI: 1.32–2.26) [31].

NIH-PA Author Manuscript

Medicaid Population
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Various studies have documented racial and ethnic disparities among Medicaid enrollees in
various state Medicaid programs in relation to access, use and expenditures on prescription
medications, and health status of enrollees (Table 2). Among the earliest studies
documenting racial and ethnic inequities in medication use among the Medicaid population
was the one by Kotzan and colleagues who intended to determine the effects of age, gender,
and race on the use of prescription drugs among a sample of Georgia Medicaid enrollees
[32]. The researchers used the Medicaid prescription claims data from 1985 for that state.
Whites were found to use a higher mean number of prescriptions when compared to nonWhites; this difference increased as age increased (P=0.05) [32]. Using the 1992 Medicaid
Statistical Information System (MSIS) data from Georgia to determine racial disparities in
prescription drug use and expenditures among the enrollees, Khandker and Simoni-Wastila
found that Black children, adults, and elderly all used fewer prescription drugs compared to
their White counterparts (43%, 30%, and 18% fewer respectively; P<0.01) [33]. Drug
spending was also higher among Whites compared to Blacks ($382 vs. $202 per enrollee).
The authors speculated that these differences resulted from either differences in severity of
illness between Blacks and Whites or from disparities in access to first-line drugs [33].
Among the dual Medicare and Medicaid beneficiaries, significant racial and ethnic
disparities were also documented in prescription drug utilization and expenditures as
reported in the previous section on Medicare population [21, 22].
Significant racial and ethnic disparities have been documented in disease-specific studies,
especially in relation to mental disorders and their treatments. In a mid-Atlantic state
Medicaid program in 2000, Zito and colleagues examined whether there were differences in
the magnitude of disparities in the use of psychotropic medications between Black and
White youths as a result of Medicaid eligibility categories [34]. Multivariate analyses
showed that White-Black disparities were significant and varied for different Medicaid
eligibility categories (range of ORs = 2.2–3.8) [34]. Depp and colleagues analyzed
longitudinal trends in the utilization of antipsychotics and mood stabilizers for bipolar
disorder treatment [35]. They used the data from California’s Medi-Cal for Medicaid
enrollees from 2001 to 2004 and found that, compared to non-Latino Whites, African
Americans and Latinos were less likely to receive antipsychotics or mood stabilizers
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(P<0.001) [35]. Horvitz-Lennon and colleagues, in their analysis of Florida Medicaid
program’s claims data for 1994 to 2006, also found significant Black-White (P<0.001) and
Hispanic-White disparities (P<0.001) in spending on psychotropic drugs [36].
Disparities in access to, and use of, HIV/AIDS pharmaceuticals have also been widely
documented in Medicaid enrollees. Crystal and colleagues analyzed merged data consisting
of administrative claims data and HIV/AIDS surveillance data from the New Jersey
Medicaid program up to 1998 [37]. Their objective was to examine the initiation of and
persistence of use of newer antiretroviral treatments administered, namely protease
inhibitors (PI) and nonnucleoside reverse transcriptase inhibitors (NNRTI), and explore any
associations with patient characteristics. African Americans and Hispanics were found to
experience approximately 8 to 9 months of delay (P<0.05) in treatment initiation compared
to Whites [37]. Additionally, less-consistent use of the PI/NNRTI treatment after the first
prescription was seen among minorities (P<0.05) [37]. King and colleagues examined the
1998 Medicaid claims data for highly active antiretroviral therapy (HAART) for five states
[38]. The authors found that non-Hispanic Blacks (P<0.001) and Hispanics (P=0.003) were
found to have significantly lower likelihood of receiving HAART compared to Whites [38].

NIH-PA Author Manuscript

Studies documenting use of some of the other classes of medications and related disease
states among Medicaid enrollees have also found racial and ethnic disparities. Lieu and
colleagues used the American Academy of Pediatrics (AAP) Children’s Health Survey for
Asthma to document asthma status and care processes reported by the parents interviewed
with the intention of investigating any racial and ethnic variations in their children’s care
[39]. Despite having worse asthma status, Black (P=0.01) and Latino children (P=0.005)
were less likely to use asthma-preventing medications than were Whites. Possible
explanations were differences in health beliefs and concepts of disease [39]. Shaya and
colleagues determined the association of race with the likelihood of being prescribed
selective cyclooxygenase-2 inhibitors (COX-2) versus any other nonsteroidal antiinflammatory agents (NSAID) [40]. They analyzed data on enrollees from a mid-Atlantic
state’s Medicaid managed care organizations. The authors found that African Americans
along with other races had a lower likelihood (OR: 0.67; 95% CI: 0.62–0.73) of being
prescribed a COX-2 as compared to Whites [40]. Litaker and colleagues analyzed the
pharmacy claims data from 1992 to 1999 in the Ohio Medicaid program to examine
disparities in cardiovascular disease prevention with respect to the use of lipid-lowering
agents, including statins, fibrates, and bile sequestrants [41]. The study found that the odds
of younger minority adults (≤60 years old) were lower for being either previous users
(P=0.01), new users (P =0.04), or long-term users (P =0.001) of lipid-lowering agents,
compared to their White counterparts [41].
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Not many studies have documented racial and ethnic disparities in health status among
Medicaid enrollees for specific conditions, and none that we found has documented
disparities in the health status in general among enrollees. However, disparities in various
other aspects of health care such as access to, use of, and expenditures for, prescription
medications and other health services, as evidenced from the studies mentioned above, can
contribute toward producing racial and ethnic inequities in the likelihood of meeting
predominantly utilization-based eligibility criteria among Medicaid enrollees.
General Population
Documented evidence examining the relationship of race and ethnicity with the utilization of
prescription medications is not extensive. The studies, generally conducted in both adults
and children, demonstrate patterns of disparities in access to, use of, and expenditures for
prescription medications (Table 3). Using the 1996 MEPS data, Chen and Chang examined
the association of various factors, including race and ethnicity, with prescription drug
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.
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expenditures among the pediatric population aged 0 to 17 [42]. Black children were found to
have approximately 33% lower likelihood of using prescription medications (P<0.001)
compared to White children. In addition, Black (P <0.001), Hispanic (P =0.025), and Asian
(P =0.010) children had significantly lower expenditures for prescription medications when
compared to White children [42]. Possible reasons according to the authors were cultural
and personal preferences and differing insurance types [42].
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Using the MEPS data from 1996 to 2001, Wang and colleagues examined racial and ethnic
disparities in the use of essential new prescription medications among adults [43]. New
medications were defined as those that existed in the market for fewer than 5 years at the
time of the MEPS data collection; essential drugs were defined as those known to prevent
worsening medical conditions, hospitalization, or death. Significant racial disparities in the
use of these drugs were observed, with Blacks obtaining fewer such drugs compared to
Whites (rate ratio (RR): 0.85; 99% C.I.: 0.73–0.98) [43]. The study found no statistically
significant ethnic disparities in the use of essential new medications. Possible explanations
for these findings were failure to fill all or refill all prescriptions, cultural barriers, lack of
trust in the health care system, and intentional or unintentional racial prejudice by health
care providers [43]. In another study using the same database and definition for new
medications, Wang and colleagues examined racial and ethnic disparities in the use of new
prescription medications [44]. They found that, compared to non-Hispanic Whites, nonHispanic Blacks used approximately 22% fewer new medications (P<0.01), according to the
5-year criterion, and approximately 26–33% fewer new drugs (P<0.01) according to other
criteria [44]. White-Hispanic differences were once again not always statistically significant.
In addition to some of the possible explanations for such findings mentioned in their
previous study, the authors suggested that lower likelihood by minorities of trying new
drugs, presence of fewer pharmacies in minority neighborhoods, and lack of availability of
new drugs in them might also have led to lower use of new prescription medications among
minorities when compared to non-Hispanic Whites [44]. More recently, a study by Chen and
colleagues examined ethnic disparities in the use and expenditure for prescription drugs
[45]. Using the MEPS data from 1999 to 2006, the authors analyzed the data for Latinos
according to various subethnicities (Puerto Ricans, Mexicans, Cubans, Central/South
Americans, and other Latinos), and compared them to Whites [45]. The study found that,
compared to Whites, Latinos were significantly less likely to use prescription drugs. Among
the subgroups, Puerto Ricans were the most likely (P<0.001), and Cubans were the least
likely (P<0.001) to use prescribed drugs. Whites also had significantly higher drug
expenditures compared to Latinos (P<0.001), although the differences between Whites and
Cubans were not statistically significant [45].
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A major portion of the empirical evidence on racial and ethnic disparities in medication use
and expenditure in the general population is either disease-specific or drug-class specific.
Much of the literature in this area has examined HIV and mental illnesses and the
medications used in their treatment. Using various patient-level factors, Smith and Kirking
examined the relationship between use of antiretroviral and pneumocystis carinii pneumonia
(PCP) medications with access to medical care [46]. They used the AIDS Costs and Services
Utilization Survey (ACSUS) data, which consisted of up to six interviews with a cohort of a
diverse group of HIV patients from 1991 to 1992. They found that non-Hispanic African
Americans (P=0.0187) and Hispanics (P=0.0044) had a higher likelihood of receiving
antiretroviral medications than did Whites and had no statistically significant difference in
the likelihood of receiving PCPs. According to the authors, this finding could be due to the
result of more severe stage of the disease among African Americans and Hispanics; thus, the
minorities in this study may not have represented the typical users of antiretroviral drugs
[46]. On the other hand, Gebo and colleagues found that, in a multistate sample of HIV
patients in 2001, African Americans had a lower likelihood of receiving HAART compared
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.
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Among the studies examining disparities in mental illness, Han and Liu investigated
disparities in the use of psychiatric drugs between Whites and Blacks, Hispanics, and Asian
Indians [48]. The researchers used the MEPS data from 1996 to 2000. Compared to Whites,
Blacks, Hispanics and Asian Indians were all less likely to use prescription drugs for mental
illnesses (P<0.01), with the difference in prescription expenditures between Blacks and
Whites being statistically significant (P<0.01) [48]. Wang and colleagues used the MEPS
data for 2002 and 2003 to determine the economic implications of racial and ethnic
disparities in use of selective serotonin reuptake inhibitors (SSRI) [49]. Non-Hispanic
Whites, on average, used a higher number of SSRIs when compared to non-Hispanic Blacks
and Hispanics (P<0.05). Additionally, non-Hispanic Blacks and Hispanic Whites had a
lower likelihood of using SSRIs compared to non-Hispanic Whites (P<0.05). Cultural
barriers, lack of trust in the health care system, and language barriers were some of the
possible explanations noted by the authors [49]. Using data from two of the National
Institute of Mental Health’s Collaborative Psychiatric Epidemiology Surveys (CPES) from
2001 to 2003, González and colleagues investigated the existence of racial disparities in the
use of antidepressants [50]. Compared to depressed White respondents, depressed Black
respondents had significantly lower odds (P<0.001) of using antidepressants in the year
before the data were collected [50].
Disparities have also been reported in the treatment of cardiovascular diseases. Winters and
colleagues studied the influence of race and health insurance on prescription medication use
and expenditures [51]. They used the MEPS data files from 1996 to 2003 to examine 18- to
64-year-old individuals who had reported any form of cardiovascular disease. African
Americans, Hispanic Americans, and persons belonging to other races filled significantly
fewer number of prescriptions (P<0.01) and had lower annual prescription medication
expenses compared to European Americans (P<0.001) [51].
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In our search for studies documenting disparities in the health status among the general
population, in accordance with our objective, we found several publications which
demonstrated the existence of such differences between minorities and Whites. In particular,
significant racial and ethnic disparities were found to exist in the prevalence of chronic
conditions, such as diabetes and hypertension. Brancati and colleagues used a prospective
cohort study approach to determine racial and ethnic differences in the incidence of type-2
diabetes [52]. They found that the incidence rate in African American women was
approximately 2.4 times greater compared to White women (P<0.001). African American
men had an incidence rate that was 1.5 times greater compared to White men (P<0.001).
African American men and women were also found to have higher blood pressures prior to
the onset of diabetes, compared to their White counterparts (P<0.05) [52]. Kramer and
colleagues examined the relationship between race and ethnicity and hypertension and its
treatment [53]. They found that African Americans (OR: 2.21; 95% CI: 1.91–2.56) and
Chinese (OR 1.30; 95% CI 1.07–1.56) had a higher likelihood of having hypertension. In
addition, African Americans had a greater likelihood of having uncontrolled hypertension,
even after being treated for it (OR: 1.35; 95% CI: 1.07–1.71) [53]. Racial and ethnic
disparities have also been documented for some cancers such as prostate and breast cancer,
indicating that minorities have higher morbidity and mortality rates compared to their
majority counterparts among individuals diagnosed with the aforementioned forms of cancer
[54, 55].
Using data from the Behavioral Risk Factor Surveillance System for 2007, Hayes and
colleagues examined race and ethnicity and socioeconomic status disparities in the health-
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related quality of life (HRQOL) among respondents with coronary heart disease [56]. The
authors found that, in comparison to non-Hispanic Whites, Hispanics had a higher likelihood
of reporting fair to poor health status (P<0.001), whereas Native Americans had the highest
odds of reporting 14 or more total unhealthy days (P=0.02) and 14 or more activity-limited
days (P=0.002). No significant differences between non-Hispanic Blacks and Asians in
comparison to Whites were found in that study [56]. Carpenter and colleagues also reported
ethnic disparities in health status with no significant Black-White disparity [57].

Discussion
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Our review consistently documented disparities in utilization of, and expenditures on
prescription medications, and in the health status between minority groups and Whites for
all three population groups; the Medicare, Medicaid, and the general population. Among the
Medicare beneficiaries and the dual eligible beneficiaries, studies have found that Blacks
and Hispanics had significantly lower use of and spending on overall prescription
medications and disease-specific medications such as antihypertensives and anti-dementia
medications [19–25]. Disparities were also found to exist in their health status, with certain
chronic conditions such as diabetes, ESRD, and obesity being more prevalent among
minorities compared to Whites, resulting in greater disability-related outcomes among them
[26–31]. Similar disparities were observed among the Medicaid enrollees in all the studies
across several drug categories such as antipsychotics, mood stabilizers, HIV, asthma and
cardiovascular medications [32–41]. Among the general population, the empirical evidence
supports the notion that significant Black-White and Hispanic-White disparities exist in the
use of and spending on HIV medications, psychiatric drugs, antidepressants, and
cardiovascular drugs [42–51]. Minorities were also found to be more likely to report poor
health status, with a greater prevalence of diabetes and hypertension among them [52–57].
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A variety of reasons and explanations have been given to account for the existence of these
disparities, such as differing socioeconomic status measures, health beliefs and patient
perceptions, severity of diseases and stage at which diagnoses were made, and even
intentional and unintentional bias in treatment by providers [19–57]. Our review clearly
demonstrates lower utilization of and spending on prescription drugs by minorities in
comparison to Whites, despite poorer health status, and greater prevalence of certain chronic
conditions among them. Two of the three criteria for being eligible to receive the muchneeded, broad range of MTM services under Part D require beneficiaries to consume a
certain number of medications; the upper threshold being 8 drugs; and incur spending of
$3,000 or more on their medications annually. It is clear from this review, and from the
findings of Wang and colleagues [16], that such utilization-based MTM eligibility criteria
have inherent disparity implications. Such criteria may further widen the gap in the care
received by minorities and their White counterparts, and may run contrary to the objectives
of various federal and state initiatives to eliminate health disparities.
In its report entitled Unequal Treatment: Confronting Racial and Ethnic Disparities in
Healthcare, the Institute of Medicine (IOM) defined healthcare disparities as “racial or
ethnic differences in the quality of health care that are not due to access-related factors or
clinical needs, preferences, and appropriateness of intervention.” [4, p. 3–4] The report
further observed that “Racial and ethnic disparities in health care exist, and are consistent
and extensive across a range of medical conditions and health care services, are associated
with worse health outcomes, and occur independently of insurance status, income, and
education. …” [4, p. 79] The empirical evidence from our review of the literature on
prescription medication use and expenditure and the health status of populations of different
races and ethnicities are consistent with the IOM report.
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“Race,” which is considered a sociopolitical construct, has been used by researchers to
allocate individuals in accordance with the levels of social stress faced and the amount of
medical care received by them [58, 59, 60]. “Ethnicity” on the other hand, is a broad social
concept that has been used to categorize individuals based on such characteristics as shared
nationality, tribal affiliation, religious faith, shared language, or cultural and traditional
origins and backgrounds [61]. The availability of high-quality data for all racial and ethnic
groups is extremely critical for researchers to be able to identify specific root causes of
disparities in various health care settings, and in turn, design measures to address them.
Under the 2010 PPACA’s Section 4302, the HHS is directed to develop and maintain
standards for collection and dissemination of demographic information for all federal health
care and public health programs, activities or surveys [105]. Apart from collecting
information on gender, geographic location, disability status, and other such variables that
can address health disparities, this provision states that the Office of Management and
Budget standards must be used at a minimum, for race and ethnicity measures [105]. An
increased availability and quality of such data can help researchers identify hitherto
unexplored areas of health inequities, thereby bolstering the efforts of various national
health and strategic planning initiatives such as the HHS Action Plan to Reduce Racial and
Ethnic Health Disparities and the Healthy People initiatives, to successfully achieve their
goals of complete elimination of racial and ethnic disparities in health care.
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In addition to the social justice argument, recent studies have also attempted to justify the
elimination of disparities from an economic perspective. In one such study by LaVeist and
colleagues, the researchers analyzed the MEPS data between 2003 and 2006, and found that
the total combined costs of health inequalities, which included the direct medical and
indirect costs of health disparities and the costs of premature death, totaled $1.24 trillion in
the U.S. during this time [62]. These direct medical expenditures and indirect costs would
have been reduced by $229.4 billion and more than $1 trillion respectively, had health
inequalities been eliminated from the health care system during the same period [62]. In
another study by Waidmann using the same database, the author estimated that in 2009, the
disparities between non-Hispanic Whites and racial and ethnic minorities would have cost
$23.9 billion to the health care system, of which the cost to Medicare alone would have been
$15.6 billion [107]. These findings indicate that inequalities in health care exert tremendous
economic burden on the overall health care system in the U.S, and eliminating them could
potentially save billions of dollars. Ensuring that policies pertaining to MTM eligibility
criteria do not perpetuate racial and ethnic disparities may thus, also lead to savings of
health care dollars.
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Disparities in health care may not always be easy to detect or eliminate. Studies
documenting racial and ethnic disparities arising from utilization-based eligibility criteria
are rare, which may suggest that such disparities are not directly perceptible. In a study by
Fishman and colleagues, African Americans with cancer were found to be more likely to be
excluded from hospice services in comparison to their White counterparts, despite the fact
that they were more likely to perceive needing such services [63]. The reason was that the
eligibility criteria for hospice services required that cancer patients give up their curative
cancer treatments; however, African Americans were found to have a strong preference for
continuing their curative treatment. MTM services, too, have stringent, utilization-based
eligibility criteria. However, the bulk of the evidence from our review of the literature shows
that racial and ethnic minorities have lower consumption of, and spending on prescription
drugs as compared to Whites, despite evidence suggesting that they have worse health status
and suffer from poorer health outcomes in comparison to their White counterparts [63].
Several legal and policy changes have taken place since the release of the Report of the
Secretary’s Task Force on Black and Minority Health in 1985. The Balanced Budget Act
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(BBA) of 1997 stipulated significant cuts in Medicare and Medicaid reimbursement to
health care providers, in addition to granting States the authority to enroll Medicaid
beneficiaries in managed care organizations (MCOs) without seeking a federal waiver [108].
The 2003 MMA established prescription drug coverage for all beneficiaries under the
Medicare Part D [7]. Research has shown that following Part D implementation in 2006,
disparities in access to medications and prescription drug expenditures have started to
decline [64]. The 2010 PPACA vastly changed the landscape of the U.S. health care system
with the most comprehensive overhaul of health care yet [105]. It includes several key
provisions that address health disparities. Chief among them are Section 5307, which
focuses on improving the diversity of the health care workforce and its competency in
treating patients of different races and ethnicities, Section 10334, which strengthens the
HHS’s administrative capabilities to address health issues of minorities, and the
aforementioned Section 4302, which advances collection of health information by race,
ethnicity and primary language [105]. Some of these long-term goals of eliminating racial
and ethnic disparities provided a strong foundation for the implementation of the HHS’s
Action Plan to Reduce Racial and Ethnic Health Disparities in 2011, with a focus on
reducing, and eventually eliminating health disparities [102]. When evaluating the Healthy
People 2010 initiative, out of the 169 objectives for which data for various racial and ethnic
groups were available, there were no changes in disparities for 111 (69%) objectives [109].
With Healthy People 2020 proposing similar goals of eliminating health disparities as
Healthy People 2010, it is imperative to understand disparity implications of policies, laws
and regulations to ensure that such disparities are reduced, and eventually eliminated in the
coming decades.
According to Dr. Jones’ theoretical framework for understanding disparities mentioned
earlier, policies or systems that lead to racial and ethnic disparities can be classified as
institutionalized causes of disparities [6]. Overlooking the empirical evidence on
prescription drug utilization, expenditures, and health status among minorities, may
perpetuate institutionalized causes of racial and ethnic disparities arising from the
utilization-based MTM eligibility criteria. Previous studies, such as the one by Fishman and
colleagues [63] and Wang and colleagues [16], have examined the institutionalized causes of
racial and ethnic disparities in health policies. The MTM eligibility thresholds are not rigid
and are subject to continuous evaluation and development [104]. Our review of the literature
indicates the existence of significant disparities in prescription drug use and spending and in
health status among various racial and ethnic groups. Future decision-making must consider
all the available evidence when contemplating policy changes to the MTM eligibility
provisions to even out any disparities among the various sections of the population.
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A major strength of our review is that it documents well disparities in drug utilization and
expenditures and in the health status between minorities and Whites to enable the readers to
understand the disparity implications of the predominantly utilization-based MTM eligibility
criteria under Medicare Part D. In addition, by including the Medicaid and the general
population in this literature, we are able to demonstrate disparity implications of these
eligibility criteria among the non-Medicare population as well. More than two decades of
research has shown that not only overall prescription drug use is lower, but disease-specific
drugs such as those for cardiovascular disorders, mental disorders, hypertension, asthma,
and HIV/AIDS, are also being consumed to a lesser extent by minorities in comparison to
Whites, resulting in lower drug spending among them. Chronic conditions such as diabetes,
hypertension, obesity, and ESRD were found to be more prevalent in minorities leading to
greater disability-related outcomes and poorer health status among minorities than Whites.
Our literature review has certain limitations. This paper is not a comprehensive compilation
of all the studies reporting racial and ethnic disparities in the use of and spending on
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prescription drugs and in health status. However, as we have mentioned before, our intent
was to present a general pattern of such disparities among the Medicare, Medicaid and the
general population, rather than present a comprehensive review. In addition, the disparities
observed in our review could be affected by certain patient level characteristics other than
race and ethnicity, such as socioeconomic status measures, geographic location, family
structure, and so on. However, most studies have adjusted for some, if not all, of these
variables, and have still found race and ethnicity to be significantly associated with health
disparities. Finally, not many studies in our review have examined disparities in Hispanics,
especially the ones before late 1990s. This could be due to the fact that Hispanics were
categorized either as Whites, or “Other race” under certain surveillance methods at that time
[65]. In a related limitation, there are very few studies documenting disparities in several
other races, such as Asians, Native Americans, and so on. This could be due to factors such
as unavailability, underreporting, and misreporting of race and ethnicity data.

Conclusion
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In summary, the evidence from our literature review indicates disparities in the use of, and
spending on prescription medications and in the health status and health states of racial and
ethnic minorities in comparison to the majority White population. Moreover, these
disparities are found in the Medicare, Medicaid, and the general population. Many
regulations and legislations have been, and continue to be, designed and implemented to
ensure equitable access to affordable health care while increasing the efficiency of health
care delivery in the country. However, utilization-based provisions of some health policies
and legislations, such as the MTM eligibility provisions under Medicare Part D, may have
inherent disparity implications. Our review indicates that, in spite of suffering from poorer
health outcomes, minorities utilize fewer prescription drugs and spend fewer resources on
acquiring them. This makes it difficult to ensure equitable access to health care for all and,
at the same time, ensure efficient allotment of resources to the provision of health care.
Future policy-making decisions must consider all the available evidence on utilization of
health care resources among all racial and ethnic groups to ensure that none of the policy
provisions perpetuate racial and ethnic disparities.

Expert Commentary
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The value of MTM services in managing chronic diseases and their treatments has been
widely recognized in the scientific world. For example, the 2010 PPACA has acknowledged
its importance in easing the burden on the Medicare system and stipulated modifications to
their eligibility criteria. Apart from Medicare, state Medicaid programs and self-insured
employers, too, offer MTM services to their enrollees. Thus, the policies and regulations
implemented by CMS and PPACA for MTM services have a far reaching impact beyond the
Medicare population.
Eliminating disparities in health care has received significant attention recently, as
exemplified by the various federal policy initiatives implemented by the HHS and under the
2010 PPACA. The purpose of our review was to highlight the subtle and implicit forms of
racial and ethnic disparities arising from predominantly value-based strategies, such as the
MTM eligibility criteria. The predominantly utilization-based eligibility requirements for
these services stand in contrast to the laudable emphasis on ensuring equitable distribution
of health care resources and comprehensive coverage and ultimately, the complete
elimination of racial and ethnic disparities from the health care system. The U.S. Census
Bureau estimates that there would be significant increases in racial and ethnic diversity in
the country in the next four decades, with the proportion of non-Hispanic Whites declining
with a corresponding increase in the proportion of many racial and ethnic minorities, over
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the same period [110]. Thus, if such disparities continue to exist, even at the current level,
the burden to society from racial and ethnic disparities may be exacerbated in the coming
decades. Although improvements are being made in bridging the gaps in care between all
racial and ethnic groups in comparison to Whites, the ultimate goal of its complete
elimination is still far from being achieved. It will require much more in-depth research in
identifying the root causes and consequences of these disparities, additional interventions at
the provider level, and more sophisticated monitoring for disparities by various public and
private agencies to achieve that goal. Future research should continue to examine the true
causes of racial and ethnic disparities and the measures that can effectively eliminate such
disparities.

Five-Year View
In the next five years, the focus will continue to be on eliminating racial and ethnic
disparities in health care with more and more studies focusing on identifying factors that
were either previously overlooked or were unaccounted for to determine the root causes of
such disparities. Specifically, more research will analyze the disparity implications of
various federal and state regulations and legislations to identify institutionalized forms of
disparities to ensure that the policymakers are better informed and are able to strike an
equity-efficiency balance when evaluating and framing health care policies in the future.
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•

Our review aimed to compile empirical evidence on the medication utilization
and spending disparities, and differences in the health status and health
conditions, between Whites and racial and ethnic minorities.

•

This review found substantial disparities between White and minority Medicare
beneficiaries with respect to medication use and health status with most of the
studies documenting minorities using fewer drugs and incurring lower
medication expenditures, despite having poorer health status.

•

Among the Medicaid population, significant racial and ethnic differences,
especially between African Americans and Whites, were found to exist in the
use of and expenditures for prescription drugs, with many studies reporting
disparities in the treatment of mental disorders and HIV/AIDS.

•

Among the general population, significant racial and ethnic disparities have
been noted overall, as well as in disease-specific prescription drug use and
spending.

•

The prevalence of certain chronic diseases was found to be greater in racial and
ethnic minorities as compared to their White counterparts.

•

Utilization-based eligibility criteria for certain important services, such as MTM
services, may have inherent bias against racial and ethnic minorities because
they use fewer medications and incur lower drug expenses compared to their
White counterparts, despite being more likely to suffer from some of the most
prevalent chronic conditions and having worse health status and health
outcomes in comparison to Whites.

•

In the next 5 years, research will continue to focus on the identification of the
true causes of racial and ethnic disparities and on the elimination of these
disparities.
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Table 1

Studies documenting disparities in the Medicare population

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Authors (Publication Year)

Study Endpoints

Data Source

Racial/Ethnic Groups Compared

Findings

Briesacher et al. (2003)19

Drug coverage and
use among Medicare
beneficiaries with
diabetes,
hypertension or heart
disease.

Medicare Current
Beneficiary Survey
(MCBS) data (1999).

Blacks, Hispanics, and Whites.

Blacks and
Hispanics used 10–
40% fewer drugs
and had
approximately 60%
lower total drug
costs compared to
Whites.

Gaskin et al. (2006)20

Prescription drug
spending and use
among Medicare
beneficiaries.

MCBS (1999).

Hispanics, non-Hispanic Blacks,
and non-Hispanic Whites.

Blacks and
Hispanics had
lower total
spending and outof-pocket spending
compared to
Whites.

Phillips et al. (2002)21

Prescription drug
costs and their
predictors among
dually eligible
enrollees in a
Medicaid home- and
community-based
service (HCBS)
program in Georgia.

Medicaid pharmacy
claims data for dually
eligible beneficiaries
in Medicaid HCBS
from four regions in
Georgia (August
1996–July 1997).

African Americans, Whites,
Hispanics, Asian and Others.

African Americans
were found to incur
significantly lower
drug expenditures
in comparison to
Whites.

Schore et al. (2003)22

Prescription drug use
among dually eligible
Medicare
beneficiaries in 10
U.S. States.

CMS’ dually eligible
beneficiary databases
for 10 U.S. States
(1995).

Blacks and Whites.

Blacks spent
approximately 20%
less per month on
prescription drugs
compared to
Whites.

Schneider et al. (2002)23

Rates of beta-blocker
use after myocardial
infarction, breast
cancer screening, eye
examinations and
follow-up visits for
mental illness among
Medicare managed
care enrollees.

Health Plan Employer
Data and Information
Set (HEDIS) (1998).

Blacks, Hispanics, Whites and
Others.

Black enrollees
were less likely
than Whites to
receive betablockers.

Zuckerman et al. (2008)24

Differences in antidementia medication
use among
community-dwelling
Medicare
beneficiaries with
dementia.

MCBS (2001–2003).

Non-Hispanic Blacks, non-Hispanic
Whites, Hispanics, and Others.

Non-Hispanic
Whites used
approximately 30%
greater antidementia drugs
compared to other
groups.

Poon et al. (2009)25

Use of and adherence
to antihypertensive
and dementia drugs
among veterans aged
65 and over,
diagnosed with
hypertension and
dementia.

2 national databases of
the Veterans Health
Administration (2000–
2005).

African Americans, Hispanics and
Whites.

Compared to
Whites, African
Americans were
less likely to
receive certain
hypertension and
dementia drugs,
and Hispanics were
less likely to
receive certain
hypertension drugs.

Gornick et al. (1996)26

Effects of race and
income on mortality
and use of Medicare
services.

Medicare
administrative data
(1993) and Census
data (1990).

Blacks and Whites.

The proportion of
surgical procedures
associated with
poor management
of chronic
conditions such as
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Authors (Publication Year)

Study Endpoints

Data Source

Racial/Ethnic Groups Compared

Findings

NIH-PA Author Manuscript

diabetes and end
stage renal disease
(ESRD), was
greater among
Blacks as
compared to
Whites.

NIH-PA Author Manuscript

McGinnis et al. (2003)28

Racial differences in
survival among HIVpositive US veterans.

Veterans Aging
Cohort 3-Site Study
(1999–2002).

Blacks, Hispanics and Whites.

Black and Hispanic
veterans had higher
mortality rates and
greater number of
medical
comorbidities
compared to
Whites.

Newsome et al. (2008)29

Racial differences in
the rate of
progression to ESRD
and mortality among
Medicare
beneficiaries.

Cooperative
Cardiovascular Project
data (1994–2004).

African Americans and Whites.

African Americans
were found to be at
a significantly
greater risk of
developing ESRD
compared to
Whites at varying
eGFR levels.

Ciol et al. (2008)30

Disability-related
outcomes such as
mobility limitation,
difficulty in six
activities of daily
living (ADLs) and six
instrumental activities
of daily living
(IADLs) among
Medicare
beneficiaries.

MCBS (1992–2004).

Native Americans, Asian, Black,
Hispanic-Whites, non-Hispanic
Whites and others.

Despite a slight
overall decrease in
the ADL and IADL
disability during
this period, racial
and ethnic
disparities in
disability outcomes
persisted,
especially BlackWhite disparities.

Whitson et al. (2011)31

Disparities between
black and white
elderly in disability
rates, controlling for
demographic and
socioeconomic
factors.

Duke Established
Populations for
Epidemiologic Studies
of the Elderly (1986–
1990).

Blacks and Whites.

Higher rates of
obesity and
diabetes mellitus in
Blacks contributed
to more than 30%
excess disability in
them in comparison
to Whites, with
Blacks having a
greater likelihood
of being obese
compared to
Whites.
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Table 2

Studies documenting disparities in the Medicaid population

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Authors (Publication Year)

Study Endpoints

Data Source

Racial/Ethnic Groups Compared

Findings

Kotzan et al. (1989)32

Influence of age, sex,
and race on
prescription drug use
among a sample of
Georgia Medicaid
enrollees.

Georgia Medicaid
Prescription
Claims Data
(1985).

Whites and non-Whites.

Whites used a higher
mean number of
prescriptions when
compared to nonWhites; the
difference in
utilization increased
with increasing age.

Khandker et al. (1998)33

Prescription drug use
and spending among
black and white
enrollees.

Medicaid
Statistical
Information
System (MSIS)
data from Georgia
(1992).

Blacks and Whites.

Black children,
adults, and elderly,
all used fewer
prescription drugs
compared to their
White counterparts.
Drug spending was
higher among
Whites compared to
Blacks.

Zito et al. (2002)34

Disparities in the use
of psychotropic
medications between
Black and White
youths.

Computerized
claims for youths
enrolled in a midAtlantic state
Medicaid program
(2000).

Whites, Blacks and Others.

White-Black
disparities were
significant and
varied for different
Medicaid eligibility
categories.

Depp et al. (2008)35

Difference by age,
gender and race/
ethnicity in the
prevalence of using
antipsychotics and
mood stabilizers for
bipolar disorder
treatment.

California’s MediCal database for
Medicaid
enrollees (2001–
2004).

African Americans, non-Latino
Whites and Latinos.

African Americans
and Latinos were
less likely than nonLatino Whites to
receive
antipsychotics or
mood stabilizers.

Horvitz-Lennon et al.
(2009)36

Racial and ethnic
disparities in spending
on psychotropic drugs,
inpatient services, all
mental health, and all
general health services.

Administrative
claims data from
the Florida
Medicaid program
(1995–2006).

Blacks, Latinos and Whites.

Significant BlackWhite and HispanicWhite disparities in
spending on
psychotropic drugs
were observed.

Crystal et al. (2001)37

The association of
initiation and
persistence of newer
antiretroviral
treatments with any
patient characteristics.

Administrative
claims data and
HIV/AIDS
surveillance data
from the New
Jersey Medicaid
program (1998).

African Americans, Whites and
Hispanics.

African Americans
and Hispanics
experienced delay in
treatment initiation
compared to Whites,
along with lessconsistent use of the
newer antiretroviral
treatments after the
first prescription
among minorities.

King et al. (2008)38

Disparities in the rates
of highly active
antiretroviral therapy
(HAART).

Medicaid claims
data of five states
(1998).

Non-Hispanic Blacks, non-Hispanic
Whites and Hispanics.

Non-Hispanic
Blacks and
Hispanics were
found to have
significantly lower
likelihood of
receiving HAART
compared to nonHispanic Whites.
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Study Endpoints
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Racial/Ethnic Groups Compared

Findings

Racial/ethnic variation
in asthma status and
management practices
among children in
managed Medicaid.

American
Academy of
Pediatrics (AAP)
Children’s Health
Survey for
Asthma (2002).

Blacks, Latinos and Whites.

Despite having
worse asthma status,
Black and Latino
children were less
likely to use asthmapreventing
medications than
were Whites.

Shaya et al. (2005)40

Association of race
with the likelihood of
being prescribed
selective
cyclooxygenase-2
inhibitors (COX-2)
versus any other
nonsteroidal antiinflammatory agents
(NSAID).

Data on enrollees
from a midAtlantic state’s
Medicaid
managed care
organizations
(2000–2002).

African Americans, Whites, Asians,
Hispanics, Native Americans and
Other or unknown.

African Americans
along with other
races had a lower
likelihood of being
prescribed a COX-2
as compared to
Whites.

Litaker et al. (2006)41

Disparities in
cardiovascular disease
prevention with
respect to the use of
lipid-lowering agents.

Pharmacy claims
data from the
Ohio Medicaid
program (1992–
1999).

Racial/Ethnic minorities and Whites.

Younger minority
adults (<60 years)
were less likely to be
either previous users,
new users, or longterm users of lipidlowering agents
compared to Whites.

Lieu et al.

(2002)39

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.

Munshi et al.

Page 24

Table 3

Studies documenting disparities in the general population

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Authors (Publication Year)

Study Endpoints

Data Source

Racial/Ethnic Groups Compared

Findings

Chen and Chang (2002)42

Factors that
influence utilization
of prescription
drugs in the
pediatric population.

Medical Expenditure
Panel Survey (MEPS)
(1996).

Asians, Blacks, Hispanics, Native
Americans, Whites and Others.

Black children had a
lower likelihood of
receiving
prescription drugs
compared to White
children; Black,
Hispanic and Asian
children had lower
expenditures
compared to their
White counterparts.

Wang et al. (2006)43

Racial and ethnic
disparities in
essential new drug
use.

MEPS (1996–2001).

Hispanics, non-Hispanic Blacks, and
non-Hispanic Whites.

Blacks used fewer
essential new
medications
compared to Whites;
no statistically
significant HispanicWhite disparities
were observed.

Wang et al. (2007)44

Racial and ethnic
disparities in new
prescription drug
use.

MEPS (1996–2001).

Non-Hispanic Blacks, Hispanics and
non-Hispanic Whites.

Compared to Whites,
Blacks used fewer
new prescription
drugs; no statistically
significant HispanicWhite disparities
were observed..

Chen et al. (2010)45

Disparities in the
use and expenditure
for prescription
drugs between
Latinos and Whites.

MEPS (1999–2006).

Latinos (Puerto Ricans, Mexicans,
Cubans, Central/South Americans,
and other Latinos) and Whites.

Compared to Whites,
Latinos were
significantly less
likely to use
prescription drugs.
Among the
subgroups, Puerto
Ricans were the most
likely and Cubans
were the least likely
to use prescribed
drugs. Whites also
had significantly
higher drug
expenditures
compared to Latinos.

Smith et al. (1999)46

Relationship
between use of
antiretroviral and
pneumocystis carinii
pneumonia (PCP)
medications with
access to medical
care.

AIDS Costs and
Services Utilization
Survey (ACSUS) data
(1991–1992).

Non-Hispanic African Americans,
non-Hispanic Whites, Hispanics and
Others.

Non-Hispanic
African Americans
and Hispanics had a
higher likelihood of
receiving
antiretroviral
medications than
Whites and had no
statistically
significant difference
in the likelihood of
receiving PCPs.

Gebo et al. (2005)47

Racial and gender
disparities in the
receipt of HAART
in a sample of HIV
patients.

10 U.S. HIV primary
care sites in the HIV
Research Network
(HIVRN) (2001).

African-Americans, Whites,
Hispanics and Others.

African Americans
had a lower
likelihood of
receiving HAART
compared to Whites.
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Disparities in the
use of psychiatric
drugs between
Whites and Blacks,
Hispanics, and
Asian Indians.

MEPS (1996–2000).

Blacks, Hispanics, Asian-Indians
and Whites.

Compared to Whites,
Blacks, Hispanics
and Asian Indians
were all less likely to
use prescription
drugs for mental
illnesses. Difference
in prescription
expenditures between
Blacks and Whites
was statistically
significant.

Wang et al. (2007)49

The economic
implications of
racial and ethnic
disparities in use of
selective serotonin
reuptake inhibitors
(SSRI).

MEPS (2002 &
2003).

Non-Hispanic Whites, non-Hispanic
Blacks and Hispanic Whites.

Non-Hispanic Whites
used a higher number
of SSRIs when
compared to nonHispanic Blacks and
Hispanic Whites.
Non-Hispanic Blacks
and Hispanic Whites
had a lower
likelihood of using
SSRIs compared to
non-Hispanic Whites.

Gonzalez et al. (2008)50

Racial disparities in
the use of
antidepressants.

National Institute of
Mental Health’s
Collaborative
Psychiatric
Epidemiology
Surveys (CPES)
(2001–2003).

Blacks and Whites.

Compared to
depressed White
respondents,
depressed Black
respondents had
significantly lower
odds of using
antidepressants.

Winters et al. (2010)51

Influence of race
and health insurance
on prescription
medication use and
expenditures.

Data on 18–64 years
old individuals with a
cardiovascular disease
from MEPS (1996–
2003).

African Americans, European
Americans, Hispanic Americans and
Others.

African Americans,
Hispanic Americans,
and persons of other
races, filled
significantly fewer
number of
prescriptions and had
lower annual
prescription
medication expenses
compared to
European Americans.

Brancati et al. (2000)52

Racial and ethnic
differences in the
incidence of type-2
diabetes.

Atherosclerosis Risk
in Communities
(ARIC) study (1986–
1989).

African Americans and Whites.

Incidence rate of
diabetes was
approximately 2.4
times greater in
African American
women, and 1.5
times greater in
African American
men, compared to
their White
counterparts. African
American men and
women had higher
blood pressures prior
to the onset of
diabetes, compared
to their White
counterparts.

Kramer et al. (2004)53

Relationship
between race and
ethnicity and

Multi-Ethnic Study of
Atherosclerosis

Whites, African Americans,
Chinese, and Hispanics.

African Americans
and Chinese had a
higher likelihood of

Han et al.

(2005)48

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2013 April 11.

Munshi et al.

Page 26

Authors (Publication Year)

NIH-PA Author Manuscript
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hypertension and its
treatment.

(MESA) study (2000–
2002).

Racial/Ethnic Groups Compared

Findings

Hoffman et al. (2001)54

Racial and ethnic
differences in
advanced-stage
prostate cancer.

Medical record
abstracts and selfadministered survey
responses from the
Prostate Cancer
Outcomes Study
(1994–1995).

Non-Hispanic Whites, African
Americans and Hispanics.

Clinically advancedstage prostate cancers
were detected more
frequently in
African-Americans
and Hispanics than in
non-Hispanic whites.

Li et al. (2003)55

Evaluate the
relationship between
race and ethnicity
and breast cancer
stage, treatments,
and mortality rates.

Surveillance,
Epidemiology, and
End Results Program
(1992–1998).

Asian or Pacific Islanders, Asians,
Blacks, Hispanic Whites, and nonHispanic Whites.

Racial and ethnic
minorities had a
greater likelihood of
presenting with an
advanced stage of
breast cancer
compared to Whites.

Hayes et al. (2011)56

Disparities in health
related quality of
life (HRQOL)
among adults with
self-reported
coronary heart
disease.

Behavioral Risk
Factor Surveillance
System state-based
telephone survey
(2007).

Non-Hispanic Whites, non-Hispanic
Blacks, Hispanics, Asians, Native
Americans, and Others.

Compared to nonHispanic Whites,
Hispanics were more
likely to report fair to
poor health status,
while Native
Americans were
more likely to report
greater number of
unhealthy and
activity-limited days.

Carpenter et al. (2011)57

Racial disparities in
health status,
HRQOL and
activity limitations
among individuals
with arthritis who
have access to
primary care
physicians.

North Carolina Health
Project (2005 &
2008).

Blacks, Latinos and Whites.

Latinos were more
likely to report fair/
poor health status
and fewer activity
limitations than
Whites or Blacks.

having hypertension.
African Americans
were more likely to
have uncontrolled
hypertension, even
after being treated for
it.
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